FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
More News related to MNTA
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Fourth Quarter and Year Ended 2009 Financial Results
- Momenta Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
- Momenta Pharmaceuticals (MNTA) volatility flat into FDA decision
- BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
- BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010
More News related to Downgrades
- Wells Fargo Downgrades Parkway Properties (PKY) to Underperform
- Piper Jaffray Downgrades Telvent Git S.A. (TLVT) to Neutral; Recommend Sidelines on Potentially Weaker Spain Business
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
FTN Equity downgrades Momenta Pharmaceuticals (Nasdaq: MNTA) to Neutral. Price target slashes 50% from $18 to $12.
To see all the upgrades/downgrades on shares of MNTA, visit our Analyst Ratings page.
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
